BACKGROUND: It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses. METHODS: In total, 98 patients with melanoma who had ipilimumab-induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy. RESULTS: Both overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P 5.002 and 0.28, P 5.001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P 5.0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P 5.02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group. CONCLUSIONS: Among patients with melanoma who had ipilimumab-induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs. Cancer
INTRODUCTION
Primary hypophysitis is a rare disorder, with an estimated annual incidence of 1 in 7 to 9 million, and it represents approximately 0.4% of pituitary surgery cases. [1] [2] [3] [4] [5] The incidence of hypophysitis after treatment with anticytotoxic T-lymphocyte antigen-4 (CTLA-4) therapy may approach 12%, although it is rare with agents targeting programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1). [6] [7] [8] Optimal management strategies for patients with primary hypophysitis and checkpoint inhibitor (CPI)-associated hypophysitis are poorly defined; therefore, treatment patterns, including glucocorticoid dosages, vary. It is unclear whether higher doses of immunosuppressive medications affect patient outcomes in primary or CPI-associated hypophysitis, whether for endocrinologic endpoints or oncologic outcomes such as survival. 9 Defects in the immune response are associated with primary and acquired resistance to CPIs. [10] [11] [12] High doses of glucocorticoids inhibit the immune response, including some pathways linked to CPI resistance. [13] [14] [15] Multiple studies have reported that immune-related adverse events (irAEs), which are often treated with glucocorticoids, may be associated with higher tumor response rates. [16] [17] [18] [19] [20] Other groups have not observed improved response rates or survival in patients with irAEs. 21, 22 Clinical studies have consistently demonstrated that patients who receive treatment with CPIs using glucocorticoids or other immunosuppressive therapy for the treatment of irAEs do not appear to have reduced survival compared with those who do not require glucocorticoids. [16] [17] [18] [19] [20] [21] [22] [23] By definition, these prior studies compared outcomes from inherently different populations, namely, individuals who had severe irAEs versus those who had minimal or no irAEs. To our knowledge, no study has examined the effects of glucocorticoids on antitumor efficacy within a group of patients who had the same irAE. Because patients with hypophysitis may receive low or high doses of glucocorticoids, this group was an ideal population to examine. We performed a comprehensive retrospective review of all patients with melanoma at Partners HealthCare-affiliated hospitals who developed ipilimumab-induced hypophysitis (IH). We analyzed the effects of different glucocorticoid doses on patient outcomes, including overall survival (OS) and time to treatment failure (TTF).
MATERIALS AND METHODS
This study was approved by the Institutional Review Board of Partners HealthCare (Boston, MA) and was performed at Massachusetts General Hospital (MGH) (Boston, MA). Patient records were searched using the Research Patient Database Registry (RPDR). The RPDR is an electronic repository of patient clinical records in the Partners HealthCare system dating to the early 1990s. The RPDR contains data from more than 7 million patients, including over 2.6 billion coded records and 130 million clinical notes. The registry may be searched by coded fields or direct text phrases. Our group has maintained an active list of all patients with melanoma who receive treatment with ipilimumab at MGH plus all associated cases of hypophysitis. The RPDR was used to identify patients who had melanoma and were diagnosed with IH at all other Partners HealthCare-affiliated hospitals. Outpatient clinical notes through August 1, 2017, were searched for the following text combination: "ipilimumab" AND "melanoma" AND "hypophysitis." The query yielded 249 patients. Records from these patients, including encounter notes, radiologic imaging, and laboratory results, were comprehensively reviewed. In total, we identified 98 patients with melanoma who were diagnosed with hypophysitis after they received treatment with ipilimumab between 2008 and 2017 at Partners HealthCare-affiliated hospitals. Nearly all patients were treated at either MGH or the Dana-Farber Cancer Institute; 42 of these patients were previously reported. 6, 24 Sixty-four patients received ipilimumab as monotherapy, and this group was used for survival analyses (34 patients received ipilimumab as part of combination or sequential therapy). Survival status of the study group was confirmed primarily by hospital medical records and also by the Social Security Death index plus public obituary records. Patients whose current vital status could not be confirmed were censored at the time of their most recent clinical follow-up. TTF was defined as the length of time between the initiation of ipilimumab and whichever occurred first: the start of another systemic therapy or death. 21 Low dose (LD) glucocorticoid therapy was defined as a maximum average daily dose of 7.5 mg prednisone or equivalent during the initial 2 months after the diagnosis of hypophysitis. High dose (HD) glucocorticoid therapy described those who received prednisone above this average dose level. Group designations were based on total glucocorticoid exposure during this period regardless of cause, including any pre-existing conditions. Average glucocorticoid doses in the patient cohort did not have a normal distribution; therefore, this value was analyzed as a categorical variable instead of a continuous unit. A notable concentration of patients received an average daily glucocorticoid dose at or below the equivalent of 7.5 mg prednisone. Median glucocorticoid doses were 5.5 mg (interquartile range [IR], 3.75-7.5 mg) and 22.4 mg (IR, 11.0-35.7 mg) in the total LD and HD groups, respectively. Median glucocorticoid doses were 5 mg (IR, 3.75-7.5 mg) and 22.4 mg (IR, 13.2-36.5 mg) in the LD and HD ipilimumab monotherapy groups, respectively. Additional information regarding glucocorticoid dose distribution, including dose tertiles and quartiles, is detailed in the Supporting Information section at the end of this article. The period of 2 months was selected due to the observation that radiographic pituitary enlargement resolved in a large majority of patients in that duration of time following the diagnosis of hypophysitis.
A diagnosis of IH was established based on the presence of new hypopituitarism and (reversible) pituitary enlargement after treatment with ipilimumab. Hormone measurements were performed before patients received exogenous glucocorticoids. Central hypothyroidism was defined as a low serum free thyroxine level with a low or inappropriately normal thyroid-stimulating hormone (TSH) or a newly low TSH level in a patient with preexisting primary hypothyroidism who was receiving a stable dose of thyroid hormone replacement. Central adrenal insufficiency was defined as an early morning serum cortisol level <3 lg/dL, a peak intravenous cosyntropinstimulated (250 lg) value < 18 lg/dL or a random level <2 lg/dL with a nonelevated adrenocorticotropic hormone level. Due to factors such as the timing or severity of clinical presentation, many patients did not have the opportunity for a more formal assessment of the hypothalamic-pituitary-adrenal axis before they received treatment with exogenous glucocorticoids. We believed that restricting the designation of central adrenal insufficiency to the first 2, more formal criteria listed above would underestimate the true prevalence of this hormone deficiency given the high prevalence of multiple pituitary hormone deficiencies at the time of hypophysitis
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Cancer September 15, 2018 diagnosis in this population, the clinical context of many patient presentations (which normally would be expected to stimulate the hypothalamic-pituitary-adrenal axis), the frequent measurement of very low random serum cortisol levels in these patients, and the extremely high percentage of patients with persistent central adrenal insufficiency after the resolution of pituitary inflammation. Central hypogonadism in men was defined as a low serum testosterone level with low or inappropriately normal luteinizing hormone or follicle-stimulating hormone levels. Central hypogonadism in postmenopausal women was defined by a lack of gonadotropin elevation and, in premenopausal women, by amenorrhea with low levels of estradiol and gonadotropins. No individual was receiving exogenous estrogen/progesterone at the time of diagnosis. Growth hormone deficiency was determined by the presence of a low age-adjusted level of insulin-like growth factor 1. Growth hormone stimulation testing was not routinely performed. Prolactin levels below 3.3 ng/mL were categorized as low. Diabetes insipidus was diagnosed if serum hyperosmolality was present accompanied by inappropriately dilute urine. Formal testing for diabetes insipidus was performed if it was clinically suspected by the presence of polydipsia and polyuria. All patients who had hypophysitis were evaluated and treated by a neuroendocrinologist. The frequency of hormone testing varied among patients according to the discretion of their physicians. With the exception of growth hormone, replacement therapy for anterior pituitary hormone deficiencies was routinely provided for all patients in the absence of any clinical contraindications. All magnetic resonance imaging (MRI) studies were reviewed by a neuroradiologist and a neuroendocrinologist.
Statistical analyses were completed using JMP (version 13, SAS Institute, Cary, NC). Values are expressed as means 6 standard error of the mean unless otherwise noted. P values < .05 were considered statistically significant. The Student unpaired, 2-tailed t test was used for group comparisons of continuous outcomes, and the Wilcoxon rank-sum test was used when data were not normally distributed, as assessed by the Wilk-Shapiro test. Group comparisons for binary outcomes were performed using the Fisher exact test, in which the effect size was estimated by odds ratios. OS and TTF rates were calculated using Kaplan-Meier estimates. Hazard ratios (HRs) were estimated using univariate and multivariate Cox regression analyses to examine the effects of greater than 1 independent variable on survival and treatment failure, and 95% confidence intervals (CIs) were calculated, where noted.
RESULTS
Ninety-eight patients who had melanoma were diagnosed with IH. Most patients were men, reflecting the sex distribution of the treated population. Most patients were diagnosed with hypophysitis after several treatment cycles (at a median of 9.8 weeks after the first dose of ipilimumab). Presentations/diagnoses that were delayed >1 month after the completion of 4 treatment cycles with ipilimumab were rare, occurring in only 6 patients. Twenty-eight patients received additional doses of ipilimumab after a diagnosis of hypophysitis (including 9 patients who already had received 4 doses); no patient had a diagnosis of recurrent hypophysitis (Table 1) .
Pituitary enlargement was observed in nearly all patients. Magnetic resonance imaging (MRI) was delayed at least 1 month following the diagnosis of hypophysitis in 8 of 11 patients where pituitary enlargement was not observed. Enlargement was mild; only 1 patient had evidence of optic chiasm compression. Radiographic changes were visible in 19 of 98 patients on prior MRI studies preceding their clinical diagnosis of hypophysitis. Resolution of pituitary enlargement occurred in all except 1 patient (this patient had follow-up imaging performed only 1 month after diagnosis, and partial radiographic improvement was noted at that time). Radiographic normalization occurred rapidly in the LD and HD groups. Resolution was present in 52% of all patients when repeat imaging was performed within 1 month, in 82% of patients within 2 months, and in 100% of patients within 3 months (Fig. 1A ). All patients who had initial follow-up MRI studies obtained later than 3 months demonstrated radiographic resolution. Resolution of pituitary enlargement was observed in 1 patient after only 4 days (Fig. 1B) . Normalization or near normalization was observed in 3 other patients within 12 days.
Headache and fatigue were the most common presenting symptoms. Multiple pituitary hormone deficiencies were present at the time of diagnosis in 69 of 98 patients (70%). The thyroid, adrenal, and gonadal axes were most commonly affected. Diabetes insipidus was not diagnosed in any patient. Pituitary function recovery occurred in many patients; however, adrenal axis recovery was rare and was observed in only 4 patients ( Table 1) .
Patients who received LD or HD glucocorticoids had similar clinical presentations, although patients in the LD group were diagnosed slightly later than those in the HD group (Table 1) . The time to radiographic resolution did not differ between the LD and HD groups (P 5 1.00 at 1, 2, and 3 months) (Fig. 1A) . In a review of encounter notes, the time course of headache resolution also did not appear to differ between the 2 groups. Pituitary function recovery was not observed more frequently among patients who received higher doses of glucocorticoids. Persistent central hypothyroidism and hypogonadism were less common in the LD group (Table 1) . Observed rates of hormone recovery were likely significantly influenced by variable timing and frequency of pituitary function assessment, as noted above (see Materials and Methods).
Oncologic outcome analyses were limited to patients who received ipilimumab as monotherapy (n 5 64). Combination therapies with ipilimumab included nivolumab (n 5 19), bevacizumab (n 5 7), granulocyte-macrophage-colony-stimulating factor (n 5 2), and nivolumab plus granulocyte-macrophage-colony-stimulating factor (n 5 1). Two patients who received sequential nivolumab followed immediately by ipilimumab also were excluded from these analyses. Clinical characteristics of the patients who received ipilimumab monotherapy are listed in Table  2 and did not differ significantly between the LD and HD groups, although there were trends toward higher baseline lactate dehydrogenase (LDH) levels and absolute lymphocyte counts in the HD group and toward a higher prevalence of BRAF mutation in the LD group. To account for potential abscopal effects, 25, 26 receipt of radiotherapy within 1 year before or after treatment with ipilimumab also was recorded.
OS and TTF were significantly higher in the LD group compared with the HD group (HR, 0.24 [95% CI, 0.07-0.61; P 5 .002] and HR, 0.28 [95% CI, 0.11-0.62; P 5 .001], respectively) ( Fig. 2A,B) . The median OS and TTF were not reached in the LD group and were 23.3 months (95% CI, 16.0-36.2 months) and 11.4 months (95% CI, 7.1-19.4 months) in the HD group, respectively. Peak glucocorticoid doses, like average daily glucocorticoid doses, had a bimodal distribution in the cohort. Group differences remained statistically significant when analyzed according to the peak glucocorticoid dose above or below a threshold of 15 mg prednisone or equivalent (data not shown).
Multivariate HRs were calculated for OS and TTF in patients with hypophysitis who received ipilimumab monotherapy. The average daily glucocorticoid dose (LD vs HD), age, sex, serum LDH level (log-transformed), tumor status (resected with no evidence of disease; yes vs no), and Eastern Cooperative Oncology Group performance status were included as covariates. LD glucocorticoid status remained a significant predictor of greater OS and TTF (HR, 0.24 [95% CI, 0.07-0.62] and 0.31 [95% CI, 0.12-0.70], respectively). Higher baseline LDH levels negatively influenced survival, as expected, and higher performance status was associated with improved survival. Older age predicted improved OS but not improved TTF (Fig. 2C) . Again, the results were similar when assessed according to the peak glucocorticoid dose, which remained a significant predictor for TTF and nearly reached significance (P 5 .08) for OS (data not shown).
Progression-free survival also improved significantly in the LD group versus the HD group (HR, 0.36; 95% CI, 0.14-0.77; P 5 .007). The median progression-free survival was 35.0 months (95% CI, 14.4-77.8 months) and 4.9 months (95% CI, 3.4-9.1 months) in the LD and HD groups, respectively.
Patients who received ipilimumab monotherapy and developed hypophysitis (n 5 64) had improved overall OS (HR, 0.53; 95% CI. 0.36-0.75; P 5 .0003) compared with those who received ipilimumab monotherapy and did not have hypophysitis (n 5 217). The median OS in patients who had hypophysitis was 28.2 months (95% CI, 20.9-47.4 months) versus 9.5 months (95% CI, 8.0-12.9 months) in those without hypophysitis (Fig. 3) . The 1-year and 2-year survival rates were 83% and 59%, respectively, in patients who had hypophysitis compared with 45% and 35%, respectively, in patients who did not have hypophysitis. OS in the HD group also remained significantly higher than OS in patients without hypophysitis (P 5 .02). 
DISCUSSION
To our knowledge, this study is the first analysis of the effects of different glucocorticoid doses on the antitumor efficacy of CPIs after the development of an irAE. Existing studies have suggested that glucocorticoid administration does not negatively impact survival in patients treated with CPIs. Importantly, all prior studies assessing the effects of glucocorticoids have compared patients who had severe irAEs (who receive glucocorticoids) with individuals who had no (or minimal) irAEs. Because irAEs may be associated with improved survival, they represent a potential confounding factor in previous analyses. Our study examined a cohort of patients who had the same irAE and received treatment with various doses of glucocorticoids. Our results suggest that higher glucocorticoid doses may negatively affect the antitumor efficacy of CPIs, as assessed by OS and TTF. These results are important for the management of patients who develop hypophysitis (and potentially other irAEs) after CPI therapy.
Patients with hypophysitis represented a rare opportunity to examine differing glucocorticoid doses in a population with a significant irAE. The relative clinical severity of many other irAEs, including the risk of death or substantial morbidity, precludes similar investigations. It is unknown whether supraphysiologic doses of glucocorticoids are beneficial in patients who have primary or CPI-associated hypophysitis. This ambiguity, combined with the ability to successfully replace deficient pituitary hormones (ie, to treat the sequelae of hypophysitis) and prior clinical observations and experience gained with IH over time, all likely contributed to the use of variable glucocorticoid doses in these patients. Pituitary gland enlargement can cause visual disturbances in a substantial number of patients with primary hypophysitis, and vision loss is a general indication for pharmacologic or surgical therapy. Gland enlargement is mild in IH patients, and visual effects are extremely rare. Surgery has therefore never been performed for IH. Radiographic resolution occurs rapidly in these patients, regardless of glucocorticoid dose. Four cases of hypophysitis actually occurred while patients were already taking glucocorticoids (5 mg prednisone daily in 1 patient and 10 mg daily in 3 others).
Headache was the most common presenting symptom in patients with hypophysitis and improved over a similar timeframe in the LD and HD groups. From an endocrinologic standpoint, higher doses of glucocorticoids did not appear advantageous. Hypopituitarism recovered only for a minority of patients in both the LD and HD groups. Lower rates of persistent central hypothyroidism and hypogonadism actually were observed in the LD group. Because of the retrospective nature of this study, patient follow-up and the frequency of hormone testing (and hormone replacement weaning) varied. These factors were likely significant contributors to the observed rates of hormone axis recovery and limited our ability to make more precise conclusions regarding the recovery of pituitary function.
Recent studies have demonstrated that defects in the immune response can contribute to primary or acquired resistance to CPI therapy. Interferon gamma(INF-c), which protects against tumor development, signals through Janus kinase 1 (JAK1) and JAK2 and is stimulated by anti-CTLA-4 therapy. 12, 13, 27 Mutations in JAK1 and JAK2 and defects in INF-c signaling have been implicated in resistance to anti-CTLA-4 and anti-PD-1 therapy. 11, 12 INF-c also promotes antigen presentation in part by the up-regulation of b-2 microglobulin. 28 Mutations in b-2 microglobulin also appear to impart resistance to treatment with CTLA-4 and PD-1 antibodies. 10 Glucocorticoids extensively modify cytokine signaling and can inhibit the interleukin-2 and INF-c pathways. [13] [14] [15] Therefore, sufficient doses of systemic glucocorticoids over an adequate timeframe would be expected to potentially affect the clinical antitumor efficacy of CPIs.
Strengths of the current study include the unique character of the study population, the very large cohort size for this specific irAE, and multisite data collection. No significant differences were present in baseline clinical characteristics of the LD and HD groups. TTF was chosen as a clinical endpoint in addition to OS as a method to eliminate confounding effects from various subsequent treatments (some of which were not clinically available over the entire study period). Differences in OS and TTF were maintained on multivariate analysis. A statistically significant survival advantage with lower glucocorticoid doses also was maintained in a sensitivity analysis with the 34 excluded patients who received combination or sequential therapy. Our results remained consistent after additional sensitivity analyses, as detailed in the Supporting Information. Limitations of our study primarily relate to the retrospective design of the analysis, which prevented standardized patient evaluation and follow-up and partly constrain attributions of causality. Our sample size was limited and restricted the number of covariates in the multivariate analysis. However, our cohort of patients with IH was several times larger than any group previously reported and constitutes a majority of all patients reported in the literature to date. 29 In the current study, patients with hypophysitis, including those who received higher doses of glucocorticoids, had improved OS compared with those who did not develop hypophysitis. This finding highlights the importance of comparing the effects of glucocorticoid doses within a population experiencing the same irAE. Treatment with HD glucocorticoids does not appear to confer any obvious advantage to patients with IH and may negatively affect tumor response to CPI therapy. We recommend against the routine use of higher doses in these patients and that such treatment should be reserved for clinical indications like visual compromise or perhaps for intractable headache. Although preliminary, our findings have potential implications for the management of other irAEs. Although the use of lower doses of immunosuppressive medications may be less of an option in many circumstances for other irAEs, therapeutic parsimony would seem desirable with more tailored regimens as the biologic mechanisms underpinning these processes are further elucidated.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Keith Flaherty serves as a consultant for Merck and Bristol-Myers Squibb outside the submitted work. The remaining authors made no disclosures.
AUTHOR CONTRIBUTIONS
Alexander T. Faje: Conceptualization, data collection and analysis, writing-original draft, and writing-review and editing. Donald Lawrence: Data collection and analysis and writing-review and editing. Keith Flaherty: Data collection and analysis and writingreview and editing. Christine Freedman: Data collection and analysis and writing-review and editing. Riley Fadden: Data collection and analysis and writing-review and editing. Krista Rubin: Data collection and analysis and writing-review and editing. Justine Cohen: Data collection and analysis and writing-review and editing. Ryan J. Sullivan: Data collection and analysis and writingreview and editing. Overall survival is illustrated after ipilimumab monotherapy in patients who had hypophysitis (1Hyp) in the lowdose and high-dose groups combined versus patients without hypophysitis.
